LDS/Medical Tests/Bone Health and Osteoporosis Management Panel

Bone Health and Osteoporosis Management Panel

Bone turnover is a process that takes place throughout our lifetimes. Bone turnover (bone metabolism) is a physiological process that maintains the balance between bone formation and reabsorption. Hormonal balance, nutrition, lifestyle and genetics are major contributing factors to bone metabolism. Genetic factors include cystic fibrosis, hemochromatosis and a family history of hip fracture. Numerous medical conditions are associated with an increased risk of osteoporosis, including sedentary lifestyle, smoking, alcohol abuse, inadequate vitamin D intake, diabetes mellitus, endocrine cancer therapy, malabsorption, gastric bypass, thalassemia, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Parkinson’s, seizure disorders, chronic kidney disease, COPD, heart failure and other conditions. Interruption of this balance during aging can lead to bone diseases such as osteoporosis, Paget’s disease and other bone related disorders.

Because bone physiology and turnover is mainly regulated by hormones, a decrease in hormones during aging might require therapies such as a special diet, hormone therapy and other special treatments. Two of the most important hormones in women that promote bone growth are estrogen and progesterone. During menopause (usually by mid-40s to 50), the levels of estrogen and progesterone start to gradually decline resulting in decreased bone mass. In men, testosterone levels decline with age (usually detectable by the mid 50s to 60), which similarly can lead to a decrease in bone mass and resultant bone disorders. Testosterone is a major source of estrogen in men. In men, testosterone is converted to estrogen; therefore, a decrease in testosterone can reduce estrogen levels resulting in bone loss. Osteoporosis is a bone disease manifested by bone fractures due to a decrease in bone mass. The Bone Health and Osteoporosis Management panel is used for evaluation of bone health and disease management. This panel tests for key hormones and metabolites involved in bone metabolism and maintenance.

Intact PTH (iPTH) 

Parathyroid hormone (PTH) is a peptide produced by the parathyroid gland. PTH is primarily involved in the maintenance of calcium homeostasis; thus, assessment of PTH can be an important diagnostic aid for diagnosis of calcium metabolism and bone disorders.

Estrogen

After menopause very small amounts of estrogens, if any, are secreted by the ovaries. Low estrogen levels cause diminished bone deposition. Low estrogen levels increase the number and activity of osteoclasts.

Vitamin D

Vitamin D is stored in adipose (fatty) tissue and enters the circulation bound to vitamin D binding protein (VDBP) and albumin. 1,25-dihydroxyvitamin D plays an integral role in calcium regulation and in the maintenance of healthy bone. In addition, it stimulates the absorption of calcium by the intestine and serves to increase calcium and phosphate reabsorption in the kidney. Primary hyperparathyroidism is usually associated with increased plasma 1,25(OH )2D. In addition to bone and calcium regulation it plays a role in hormone and metabolism as well as in immunity.

Calcium

Serum calcium levels, and hence the body content, are believed to be controlled by parathyroid hormone (PTH), calcitonin, and vitamin D. An imbalance in any of these modulators leads to alterations of the tissue and serum calcium levels, which are also regulated by the calcium levels themselves.

Calcitonin

Calcitonin is involved in calcium homeostasis, and its secretion is regulated mainly by extracellular calcium concentration. Interestingly, calcitonin specifically binds to osteoclasts, and it has been suggested that it has an inhibiting role on bone formation, such as the calcitonin "knock-out" gene experiment in mice that showed a significant increase in bone formation.

Type I collagen degradation (DPD)

Type I collagen degradation by-product is a marker for bone reabsorption.

Intact N-Terminal Propeptide of Type 1 Procollagen (PINP)

PINP is one of the most often used markers and indicators of bone formation, and is mostly used for monitoring bone formation therapies and anti-resorptive therapies. PINP is very useful in monitoring osteoporosis as it can monitor bone turnover and metabolism. Although bone density measurement is the gold standard in osteoporosis diagnosis, PINP measurement can aid in determination of severity of disease.

Progesterone

Promotes new bone formation and deposition. 

Testosterone

Helps reduce bone loss, and has a role in bone formation.

Cortisol

Glucocorticoids directly inhibit bone formation by decreasing cell proliferation and the synthesis of DNA, protein and collagen. Glucocorticoid-induced bone loss results from lower activity and higher death rate of osteoblasts on the one hand, and from increased bone resorption due to prolonged life span of osteoclasts on the other. Glucocorticoids may potentiate the proresorptive actions of parathyroid hormone and Vitamin D on bone, which contribute to net bone resorption.

FSH

Bone loss during or after menopause has been attributed to a drop in estrogen levels. Recent studies show that high FSH is required for hypogonadal bone loss. In early menopause, FSH levels show a sevenfold increase over values found in young menstruating women. In perimenopause and postmenopause, FSH is correlated with: bone loss and osteoporosis, sleep disturbances, hot flashes and night sweats.

DHEA, DHEA-S

Enhances bone deposition and remodeling. Decreases bone resorption and increases bone formation. Intact N-Terminal Propeptide of Type 1 Procollagen (PINP)

Osteocalcin

Osteocalcin is the major non-collagen calcium binding protein and it is excreted by osteoblasts in the bone. The serum concentrations are an indication of bone formation. The synthesis of osteocalcin is vitamin D independent. Elevated results are usually associated with increased bone turnover such as what is seen in osteoporosis.

Alkaline Phosphatase

More than 80% of this enzyme activity originates from liver and bone. Increased serum ALP levels provide useful but nonspecific indication of liver or bone disease.

Phosphorus

Phosphorus, along with calcium, functions to build stronger bones and teeth. Serum phosphate concentrations are dependent on parathyroid gland function, kidney function, absorption in the intestine, bone and cell metabolism, and diet.

  • Evaluation of bone health or screening for bone disorders such as osteoporosis and bone loss
  • Monitoring and managing hormone replacement therapy in osteoporosis
  • As aid in diagnosis of other bone diseases and disorders
  • Managing other bone disease treatment
See individual tests for interpretation.

See individual tests.

 

 

See individual tests for methodology.

See individual tests for specimen collection and handling.

Bone mineral density (BMD), N-telopeptide, C-telopeptide, Pyridinium crosslinks, Urinary osteocalcin, Bone specific alkaline phosphatase, CBC, serum Albumin, Serum protein electrophoresis, Serum free light chain, serum Creatinine, TSH, Tissue transglutaminase antibody, Urinary calcium excretion, Liver function tests, Total testosterone in men, Calculated free or bioavailable testosterone in men, 24 Hour urinary calcium excretion.
2-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • JAMA. 2001; 285:785-95. [PMID: 11176917]
  • Clin Calcium. 2009 Dec;19(12):1815-21. [PMID: 19949273]
  • J Clin Endocrinol Metab. 2012 Jan;97(1):179-89. [PMID: 22013106]
  • Ann Clin Biochem. 2006 Jan;43(Pt 1):3-12. [PMID: 16390603]
  • Expert Opin Pharmacother. 2008 Jan;9(1):107-18. [PMID: 18076342]
  • Bone Miner Res. 1999; 14(9):1614-21. [PMID: 10469291]
  • J Clin Pharmacol. 2002; 42(3):190-6. [PMID: 11865965]
  • Bone. 1998; 23(5):471-7. [PMID: 9823455]
  • Altern Med Rev. 2008 Mar;13(1):6-20. [PMID: 18377099]
  • Clinical Biochemistry. 2012; 45: 928-935. [PMID: 22504058]
  • Clinica Chimica Acta. 2004; 350: 167-173. [PMID: 15530474]
  • Scand J Clin Lab Invest. 2002; 62(3):237-43. [PMID: 12088343]
  • Endes DB and Rude RK. "Mineral and Bone Metabolism." Tietz Textbook of Clinical Chemistry, 3rd ed. Burtis CA, Ashwood ER (eds). Philadelphia, PA: WB Saunders Co, 1999, 1349-457.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login